This study elucidates a drug resistance mechanism in RCC cells that attenuates the sensitivity of RCC cells to sunitinib by upregulating the expression of SREBP-1, and that the resistance of RCC cells to sunitinib can be reversed by inhibiting the related mechanisms (Figure 6). The gene discussed is SREBF1; the disease is renal cell carcinoma.